July sales up 5-6%, no trade inventory build-up, MT/CSD under pressure. We are increasing FY21/22/23 EPS estimates of Dabur India by 8%/5.7%/4.3% following sales PAT beat in 1Q mainly led by Rs1.4bn incremental sales from new launches in Sanitizers and Healthcare products. Dabur is currently riding on rising consumer demand for immunity boosters and hygiene products...